Business Wire - October 12, 2005

Millennium Biotechnologies, Inc., (OTCBB: MBTG), a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional formulas, recently launched a new website -- www.RESURGEX.com. The site, which provides ordering and product information for patients and healthcare professionals on the Resurgex line of products, was designed by Blue Diesel, a leading interactive communications agency serving the healthcare industry. Blue Diesel is a subsidiary of inChord Communications Inc., one of the top ten largest healthcare marketing organizations in the world.

The launch of the website was timed to coincide with the recent national launch of the Resurgex Select(TM) line of products that focus on the nutritional needs of the oncology patient undergoing treatment.

Resurgex(R) and Resurgex Plus(R), Millennium's flagship products, are patented, advanced nutritional formulas developed to address fatigue, quality of life, and other special needs of chronically ill individuals with compromised immune systems. They are particularly beneficial for use in patients with HIV/AIDS and cancer.

Blue Diesel designed the site to be a resource for oncology patients seeking nutritional information throughout their continuum of care as an adjunct to their medical treatment. It was also developed to assist patients and health care practitioners in understanding and discerning the differences between the entire Resurgex line of products and their versatility in use. "Blue Diesel has successfully created an inviting online environment that makes it simple for consumers and medical professionals to learn more about the Resurgex products. In addition, the site makes ordering fast and efficient with an easy three-step process. Lastly, the site will provide patients with important information about nutrition during each stage of their cancer care. We are confident that it will be a valuable resource for our customers," said Jerry Swon, president and chief executive officer of Millennium Biotechnologies.

"For many oncology patients, the Resurgex products are more than just nutritional formulas - they are a critical part of their medical treatment. We were very pleased to have the opportunity to partner with Millennium Biotechnologies to build a website to make these products easily accessible to those who need them," said Kelly Gratz, president of Blue Diesel.

For additional information on the Resurgex product line, please contact Frank Guarino, Chief Financial Officer, at FGuarino@milbiotech.com or call (908) 604-2500.

About Blue Diesel

Based in Columbus, Ohio, Blue Diesel is a multifaceted interactive communications company that strategically blends direct marketing, interactive technology and creative design to provide effective marketing solutions. For more information on Blue Diesel, please go to www.bluediesel.com.

About Millennium Biotechnologies

Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(R) and RESURGEX Plus(R), are designed to assist in strengthening cellular defense and supporting the immune system in patients with HIV/AIDS, Hepatitis C, cancer and other chronic illnesses. Millennium Biotechnologies also owns the exclusive medical-market rights to GliSODin(TM) (SOD/gliadin), the only orally effective form of the important antioxidant SOD (superoxide dismutase). Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTC BB:MBTG.OB). For more information about Millennium Biotechnologies, please call (908) 604-2500 or visit www.resurgex.com.

This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

CONTACT: Millennium Biotechnologies, Inc.

Frank Guarino, 908-604-2500

FGuarino@milbiotech.com

SOURCE: Millennium Biotechnologies, Inc.

051012
BW051010

Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .